Myeloma Center Video Library

Castleman Disease Collaborative Network
Dr. Faith Davies--Future Monoclonal Antibodies: BCMA and Beyond
The genetics of multiple myeloma and how we can use it to improve outcomes by Dr. Gareth Morgan
The myeloma genome project and the aim to disseminate this worldwide by Dr. Gareth Morgan
The Myeloma Genome Project: Designing personalized therapy for multiple myeloma by Dr. Gareth Morgan
Myeloma 2017: Identifying the drivers of multiple myeloma by Dr. Gareth Morgan
Myeloma 2017: Why one size should not fit all for multiple myeloma by Dr. Gareth Morgan
Myeloma 2017: Game-changing drug classes for multiple myeloma by Dr. Gareth Morgan
ASH 2017: Novel oncogenes and tumor suppressor genes in newly diagnosed multiple myeloma by Dr. Gareth Morgan
Lymphoma & Myeloma 2017: Sequencing the genome in myeloma: Pitfalls and opportunities in the clinic by Dr. Gareth Morgan
MCRT Jackson 2017: Personalized Medicine by Gareth Morgan, MD
Myeloma Crowd Roundtable Jackson 2017: Myeloma Expert Panel Q & A (afternoon session)
Myeloma Crowd Roundtable Jackson 2017: Monitoring Your Disease by Gareth Morgan, MD
Myeloma Crowd Roundtable Jackson 2017: Myeloma Genomics by Faith Davies, MD
ASH 2017: Are Experts Personalizing Therapy to the Genetics of a Patient’s Myeloma
Should I Discontinue or Continue Revlimid If I Remain MRD Negative?
Why Doesn’t Transplant Cure Multiple Myeloma?
Any Updates on the Use of the New Immuno-Drugs for Maintenance in Myeloma?
Does a Myeloma Patient Need to Be in Remission to Benefit From the Black Swan Initiative?
Will Circulating Tumor DNA Test Replace Bone Biopsy Test in Myeloma?
Why do many MM patients relapse after being treated with targeted therapy?
Living Well With Multiple Myeloma: Understanding Genetics and Developing Research
Optimal Timing for Transplantation in Myeloma
MRD Negativity in Multiple Myeloma
Risk Stratification for Myeloma
Goals of Therapy for Symptomatic Myeloma
Frontline treatment for young multiple myeloma patients
Are we ready for mutational directed treatment: addressing the genomic basis of myeloma
Novel kinase targets as emerging therapies for multiple myeloma
The importance of the microenvironment in multiple myeloma
An all-molecular diagnostic approach for myeloma
Treatment at first relapse in multiple myeloma: how to choose a drug?
Is FISH becoming obsolete in multiple myeloma?
Utilizing new understanding in multiple myeloma biology to guide treatment
The FORTE clinical trial of carfilzomib in multiple myeloma
Identification of high-risk disease using molecular profiling by Mymap
The clinical implications of progenitor cells in multiple myeloma
The mechanisms driving relapse in multiple myeloma
Myeloma 2016: Panel discussion on the new treatment paradigm
Myeloma 2016: Panel discussion on the status of genomics
Should Multiple Myeloma Patients Undergo Genetic Testing?
Myeloma Remission: Managing Life After Treatment
Where Does Immunotherapy Fit in With Myeloma Treatment?
An Expert Explains Why to Consider a Myeloma Clinical Trial
How to Take of Yourself and Prevent Infection With Myeloma
How Oncology Social Workers Can Help
Transplant as an Effective Treatment for Multiple Myeloma
An Explanation of Myeloma
Care Partner Support: Working Together as a Couple
nspiring and Encouraging Words From a Myeloma Survivor
Expert Perspective: Maximizing and Understanding Myeloma Treatment Approaches
Expert Perspective: Optimizing Care Through Clinical Trials for Myeloma
UAMS -- Cancer and Myeloma Treatment -- Sean's Story
My advice to myeloma patients
David Fajgenbaum Survivor Story
Andy Shapira - A Patient Testomonial
Why should I travel to Arkansas to be treated for multiple myeloma?
Drug Trial for Castleman’s Gets Amazing Results
What do I need to know about multiple myeloma?
Why should I be treated at an academic medical center?
Conquering Cancer: Jerry Frazier
Meet the Myeloma Center Frits van Rhee